12-1-7 ⓔ文献
Ginès A, Escorsell A, et al: Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology, 1993; 105: 229–236.
Sort P, Navasa M, et al: Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med, 1999; 341: 403–409.
Ring-Larsen H, Palazzo U: Renal failure in fulminant hepatic failure and terminal cirrhosis: a comparison between incidence, types, and prognosis. Gut, 1981; 22: 585–591.
Zhang J, Fallon MB: Hepatopulmonary syndrome: update on pathogenesis and clinical features. Nat Rev Gastroenterol Hepatol, 2012; 9: 539–549.
European Association for the Study of the Liver: EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol, 2010; 53: 397–417.
Swanson KL, Wiesner RH, et al: Natural history of hepatopulmonary syndrome: impact of liver transplantation. Hepatology, 2005; 41: 1122–1129.
Fernández J, Navasa M, et al: Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. J Hepatol, 2004; 41: 384–390.
Fernández J, Navasa M, et al: Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology, 2007; 133: 818–824.
Cavallin M, Kamath PS, et al: Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology, 2015; 62: 567–574.
Esrailian E, Pantangco ER, et al: Octreotide/midodrine therapy significantly improves renal function and 30–day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci, 2007; 52: 742–748.
Gupta K, Rani P, et al: Noradrenaline for reverting hepatorenal syndrome: a prospective, observational, single–center study. Clin Exp Gastroenterol, 2018; 11: 317–324.